{'fraction_non_alphanumeric': 0.008710801393728223, 'fraction_numerical': 0.0, 'mean_word_length': 5.839285714285714, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Progesterone receptor modulators in gynaecological practice

The sex steroid progesterone plays a major role in the regulation of female reproductive activity. Many synthetic progestogens have been developed and introduced into clinical practice and as contraceptive agents they have revolutionized fertility control and the management of benign gynecological conditions such as endometriosis. This article discusses the development of progesterone receptor modulators (PRMSs) and focuses on the evidence for the use of the PRMs that have been administered in clinical trials to date. Mifepristone is licensed for use in termination of pregnancy buts its potential advantages for use in contraception management of heavy menstrual bleeding uterine fibroids and endometriosis as well as in non-gynecological and oncological conditions have also been highlights. The further development of related compounds including Asoprisnil and Ulipristal has been obstructed by the controversial political issues concerning their abortifacient properties. In the future it is hoped that long-term studies will confirm the safety and efficacy of these compounds.